Skip to content
Search

Latest Stories

Reliance reports record quarterly profits

INDIAN oil-to-telecoms giant Reliance Industries reported record quarterly net profits on Friday (17), boosted by strong growth in its retail businesses despite falling refining margins.

The Mumbai-based company owned by Asia's richest man Mukesh Ambani said its consolidated net profit for the quarter-ended December rose 13.5 percent to Rs 116 billion from Rs 102bn reported for the same quarter a year earlier.


"The third quarter results for our energy business reflects the weak global economic environment and volatility in energy markets," Reliance chairman Ambani said in a statement.

The company said its gross refining margin, the profit earned from each barrel of crude, was down to $9.2 in the December quarter from $9.4 in the previous quarter.

Refining margins are a key profitability gauge for Reliance, which operates the world's biggest refining complex in India's Gujarat state.

The company said profits for its telecom arm Jio jumped 62 per cent to Rs 13.5bn for the quarter, with a total 370 million subscribers.

On Thursday (16) Jio became India's top operator in terms of subscribers and revenue, three years after its launch, official data showed.

The announcement came as Jio's chief competitors, Bharti Airtel and Vodafone Idea, lost an appeal against paying a combined $7bn in past spectrum and licence fees as ordered by the Supreme Court last year.

Jio, which escaped with a relatively light $1.8bn bill, is seen as the only beneficiary of the November decision.

Ambani had launched Jio with much fanfare in September 2016, offering free services up to March 2017 and sparking intense price wars that saw consolidation in the Indian telecom sector.

Reliance is expected to roll out its e-commerce initiative later this year and has been conducting trials with mom-and-pop stores to test its payment devices, with the aim of connecting small shops with consumers.

Reliance is India's most valuable company with a market capitalisation of over Rs 10 trillion.

Shares of Reliance Industries were up almost three per cent in Mumbai as the markets closed Friday ahead of the announcement.

(AFP)

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less